Tinzaparin Sodium

Phase 3Small molecule

UUniversity of Calgary

Tinzaparin Sodium is one of 27 small molecule programs targeting Prophylaxis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProphylaxisRecruiting

ProphylaxisPhase 3

Recruiting

Competition

Competitive Landscape

27 competitors in Prophylaxis

#DrugCompanyPhaseTrials

Lovenox

Sanofi

Approved

13 2

Eliquis

Bristol-Myers Squibb

Approved

2 3

Bayer Aspirin

Bayer

Approved

2 4

Cymbalta

Jazz Pharmaceuticals

Approved

1 5

Xarelto

WWim Janssens

Approved

4 6

Coreg

Akero Therapeutics

Approved

4 7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 8

Cabenuva

GSK

Phase 3

2 9

Lovenox

Sanofi

Phase 3

1 10

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Prophylaxis

NCT05735639

Clinical

Trials by Indication[1]

Venous Thromboembolism2 trials

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03090880·59 enrolled

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

Terminated·UUniversity of Southern California·Phase 2·NCT00981903·131 enrolled

Deep Vein Thrombosis2 trials

Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin

Completed·UUniversity of Calgary·Phase 4·NCT00203658·400 enrolled

Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)

Completed·UUniversity of Calgary·Phase 4·NCT00203580·910 enrolled

Kidney Cancer1 trial

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Unknown status·UUniversity of Vermont·Phase 1/2·NCT00293501·35 enrolled

Ischemic stroke1 trial

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00061373·18 enrolled

Prophylaxis1 trial

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Recruiting·IImperial College London·Phase 4·NCT05735639·6,660 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Tinzaparin Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tinzaparin Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tinzaparin Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Calgary

Tinzaparin Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Venous Thromboembolism2 trials

Deep Vein Thrombosis2 trials

Kidney Cancer1 trial

Ischemic stroke1 trial

Prophylaxis1 trial

References

Drug Info

Quick Facts

Related News